HDFC Bank has announced that its Board of Directors approved a capital infusion of up to ₹1,000 crore into its subsidiary, HDFC Life Insurance Company Limited. The investment will be executed through a preferential issue of equity shares and can be completed in one or more tranches. This strategic move is subject to necessary regulatory clearances, including approval from the Reserve Bank of India.
Strategic Capital Infusion
On April 16, 2026, the Board of Directors of HDFC Bank formally approved a plan to invest up to ₹1,000 crore in HDFC Life Insurance Company Limited. As a subsidiary of the bank, this capital boost is intended to support the growth and operations of the insurance entity. The investment will be facilitated via a preferential issue of equity shares.
Execution and Approvals
The bank confirmed that the investment may be carried out in one or more tranches, providing flexibility in executing the capital deployment. While the board has granted its approval, the transaction remains subject to customary regulatory scrutiny and is contingent upon receiving necessary approvals from the Reserve Bank of India. The pricing of the equity shares will adhere strictly to the established guidelines for preferential issues.
Source: BSE
